# RAS Peptide Profiles in Patients With Arterial Hypertension

> **NCT02449811** · — · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 107 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Perindopril
- **DRUG:** Olmesartan
- **DRUG:** Amlodipine
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT02449811
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2018-08
- **Final completion:** 2018-11
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2019-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02449811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02449811, "RAS Peptide Profiles in Patients With Arterial Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02449811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*